A prospective observational study of patients with metastatic castration resistant prostate cancer progressing after standard hormonal therapy suitable for abiraterone acetate treatment
Project objectives
A prospective, multicenter, observational study of patients with metastatic castration-resistant prostate cancer progressing after standard hormonal therapy eligible for treatment with abiraterone acetate. This study aims to evaluate the efficacy of abiraterone acetate in standard clinical practice in terms of PSA reduction, radiographic disease-free survival, and duration of clinical benefit.
Start and end date
18/05/2016 - ongoing
Project managers
Dr. Michele Fiore
Coordinating institution of the project
Medical Oncology National Cancer Institute, Milan
Funding sources
Janssen-Cilag SPA
